Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$1.19
-$0.03(-3.56%)
At close: 4:00 PM EST
$1.19
-$0.03(-3.56%)
Day’s Range― - ―
52-Week Range$0.29 - $3.83
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.91M
Market Cap
$100.24M
Enterprise Value$73.82M
Total Cash (Recent Filing)$31.13M
Total Debt (Recent Filing)$465.00K
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding89,498,020
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-572.26
Enterprise Value/Ebitda-3.82
Forecast
1Y Price Target
$3.50Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetVery low debt and a positive equity base reduce refinancing risk and give the company financial flexibility to support clinical programs. For a pre-revenue biotech, minimal leverage lowers bankruptcy probability and preserves optionality to time external financings or partnerships.
Regulatory Clarity For Phase 3Written FDA feedback aligning on endpoints and trial design materially de-risks the path to a registrational program. That regulatory clarity enables efficient Phase 3 planning, helps attract partners or investors, and raises the odds that a successful program can support an NDA submission.
Positive Clinical Data & Ongoing TrialsRobust Phase 2 signals in DLB plus a fully grant-funded Alzheimer’s Phase 2 reduce binary risk and conserve cash. Demonstrated efficacy and convenient oral dosing strengthen commercial prospects and can support expanded development or partnering across neurodegenerative indications.
Bears Say
Pre-revenue With Persistent LossesSustained operating losses and negative free cash flow mean the company cannot self-fund late-stage trials. Continued high R&D spend without product revenue forces reliance on external capital, which can compress strategic options and increase dilution over time.
Limited Cash Runway Timing RiskProjected funding into Q2 2027 creates a timing mismatch with planned registrational activity expected to begin mid-2027. That gap raises the likelihood of near-term financing, potential delays in studies, or constrained trial execution if capital is not secured on acceptable terms.
Equity Dilution / Negative ReturnsDeclining equity and deeply negative ROE reflect repeated losses and potential dilution from financings. Over the medium term, continued value erosion without clinical success undermines shareholder returns and may force unfavorable funding or partner terms.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.29 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $100.24M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 42 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.018.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 89,498,020 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 4.31%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (194.12% Upside)
$3.50 (194.12% Upside)
Hedge Fund Trend
Decreased
By 151.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $32.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
-72.68%
Trailing 12-Months
Asset Growth
53.79%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant progress in clinical efficacy signals and strategic cost management, extending the cash runway. However, challenges remain with increased net losses, NASDAQ compliance issues, and uncertain funding partnerships. The sentiment is balanced by advancements in manufacturing and patent filings.View all CGTX earnings summariesCGTX Stock 12 Month Forecast
Average Price Target
$3.50
▲(194.12% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
10.81% Insiders
4.31% Mutual Funds
14.32% Other Institutional Investors
67.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---